WHO ICTRP trial
A study testing if adding tablets and a small dose of immunotherapy to standard…
CTRI/2025/11/097637 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2025/11/097637 |
|---|---|
| Public title | A study testing if adding tablets and a small dose of immunotherapy to standard chemotherapy makes treatment more effective for men with penile cancer before surgery. |
| Scientific title | A Phase II Randomized Trial of Neoadjuvant Chemotherapy With or Without Triple Oral Metronomic Chemotherapy and Low-Dose Immunotherapy in Resectable Locally Advanced Penile Squamous Cell Carcinoma |
| Primary sponsor | Tata Memorial Hospital |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | India |
| Conditions | Health Condition 1: N489- Disorder of penis, unspecified |
| Interventions | Intervention1: Neoadjuvant chemotherapy plus triple-OMCT plus low-dose nivolumab: Neoadjuvant intravenous weekly paclitaxel 80mg/m2 plus intravenous carboplatin AUC-2 plus triple-oral metronomic chemotherapy (tablet methotrexate 9mg/m2… |
| Registration date | Nov 18, 2025 |
| Target size | 100 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: